title: Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma.
abstract: PurposeThe purpose of this study is to present the outcomes of a series of patients with choroidal neovascular membrane (choroidal neovascularisation (CNV)) secondary to a choroidal osteoma undergoing anti-VEGF monotherapy.Patients and methodsRetrospective series of patients with choroidal neovascularization secondary to choroidal osteoma. All patients underwent clinical and imaging assessment (fundus photo, B-scan ultrasonography, fluorescein angiography, and optical coherence tomography-where available), and were managed with intravitreal anti-VEGF injections (Bevacizumab). Visual acuity and central retinal thickness were recorded pre treatment and at the end of the follow-up period.ResultsEight patients were included in this study. Of this, 6/8 had predominantly classic or classic and 2/8 patients had minimally classic or occult CNV. Each patient received 3-10 injections of bevacizumab. Median follow-up was 9 months (3-15 months). Visual acuity improved in 5 patients, by 2-6 Snellen lines. CNV completely regressed in 5 cases and partially regressed in 3 cases. Mean CRT reduction was 122 μm (6 to -230 μm).ConclusionIntravitreal bevacizumab can be an effective treatment modality in the management of vision threatening CNV secondary to choroidal osteoma.
authors.affiliation: Ocular Oncology Service, St Bartholomew's and Moorfields Eye Hospitals, London, UK.|Medical Retina Service, Moorfields Eye Hospital, London, UK.
authors.forename: V P
authors.initials: VP
authors.lastname: Papastefanou
authors.affiliation: Medical Retina Service, Moorfields Eye Hospital, London, UK.
authors.forename: M
authors.initials: M
authors.lastname: Pefkianaki
authors.affiliation: Ocular Oncology Service, St Bartholomew's and Moorfields Eye Hospitals, London, UK.
authors.forename: L
authors.initials: L
authors.lastname: Al Harby
authors.affiliation: Ocular Oncology Service, St Bartholomew's and Moorfields Eye Hospitals, London, UK.
authors.forename: A K
authors.initials: AK
authors.lastname: Arora
authors.affiliation: Ocular Oncology Service, St Bartholomew's and Moorfields Eye Hospitals, London, UK.
authors.forename: V M L
authors.initials: VM
authors.lastname: Cohen
authors.affiliation: Medical Retina Service, Moorfields Eye Hospital, London, UK.
authors.forename: R M
authors.initials: RM
authors.lastname: Andrews
authors.affiliation: Ocular Oncology Service, St Bartholomew's and Moorfields Eye Hospitals, London, UK.|Medical Retina Service, Moorfields Eye Hospital, London, UK.|UCL Institute of Ophthalmology, London, UK.
authors.forename: M S
authors.initials: MS
authors.lastname: Sagoo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D002828:Choristoma / Q000150:complications / Q000188:drug therapy*; D002830:Choroid Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010016:Osteoma; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab